235 related articles for article (PubMed ID: 15885603)
41. Four novel ULBP splice variants are ligands for human NKG2D.
Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
[TBL] [Abstract][Full Text] [Related]
42. [Expression and significance of NKG2D ligands in 13 tumor cell lines].
Wang YP; Zhang C; Niu JF; Zhang JH; Xu XQ; Wang JF
Ai Zheng; 2008 Mar; 27(3):243-8. PubMed ID: 18334111
[TBL] [Abstract][Full Text] [Related]
43. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
44. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
[TBL] [Abstract][Full Text] [Related]
45. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
46. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
47. [The roles of soluble MICA in immune escape of breast tumor].
Ye YB; Zhou ZF; Chen Q; Li JY; Chen X; Huang WW
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep; 24(9):904-7. PubMed ID: 18782524
[TBL] [Abstract][Full Text] [Related]
48. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
Mincheva-Nilsson L; Baranov V
Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
[TBL] [Abstract][Full Text] [Related]
49. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
[TBL] [Abstract][Full Text] [Related]
50. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
[TBL] [Abstract][Full Text] [Related]
51. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.
Clayton A; Al-Taei S; Webber J; Mason MD; Tabi Z
J Immunol; 2011 Jul; 187(2):676-83. PubMed ID: 21677139
[TBL] [Abstract][Full Text] [Related]
52. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells.
Coudert JD; Zimmer J; Tomasello E; Cebecauer M; Colonna M; Vivier E; Held W
Blood; 2005 Sep; 106(5):1711-7. PubMed ID: 15886320
[TBL] [Abstract][Full Text] [Related]
53. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.
Cerwenka A; Lanier LL
Tissue Antigens; 2003 May; 61(5):335-43. PubMed ID: 12753652
[TBL] [Abstract][Full Text] [Related]
54. Membrane-bound versus soluble major histocompatibility complex Class I-related chain A and major histocompatibility complex Class I-related chain B differential expression: Mechanisms of tumor eradication versus evasion and current drug development strategies.
Suresh PK
J Cancer Res Ther; 2016; 12(4):1224-1233. PubMed ID: 28169232
[TBL] [Abstract][Full Text] [Related]
55. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008.
Ashiru O; López-Cobo S; Fernández-Messina L; Pontes-Quero S; Pandolfi R; Reyburn HT; Valés-Gómez M
Biochem J; 2013 Sep; 454(2):295-302. PubMed ID: 23772752
[TBL] [Abstract][Full Text] [Related]
56. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells.
Hedlund M; Nagaeva O; Kargl D; Baranov V; Mincheva-Nilsson L
PLoS One; 2011 Feb; 6(2):e16899. PubMed ID: 21364924
[TBL] [Abstract][Full Text] [Related]
57. [Exosomes and anti-tumour immunotherapy].
Chaput N; Andre F; Schartz NE; Flament C; Angevin E; Escudier B; Zitvogel L
Bull Cancer; 2003; 90(8-9):695-8. PubMed ID: 14609758
[TBL] [Abstract][Full Text] [Related]
58. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.
El-Gazzar A; Groh V; Spies T
J Immunol; 2013 Aug; 191(4):1509-15. PubMed ID: 23913973
[TBL] [Abstract][Full Text] [Related]
59. Natural Killer Cell Phenotype and Functionality Affected by Exposure to Extracellular Survivin and Lymphoma-Derived Exosomes.
Ferguson Bennit HR; Gonda A; Kabagwira J; Oppegard L; Chi D; Licero Campbell J; De Leon M; Wall NR
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513976
[TBL] [Abstract][Full Text] [Related]
60. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival.
Mincheva-Nilsson L; Nagaeva O; Chen T; Stendahl U; Antsiferova J; Mogren I; Hernestål J; Baranov V
J Immunol; 2006 Mar; 176(6):3585-92. PubMed ID: 16517727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
